Stay updated on Mirvetuximab in Platinum-Sensitive Gynecologic Cancer Clinical Trial
Sign up to get notified when there's something new on the Mirvetuximab in Platinum-Sensitive Gynecologic Cancer Clinical Trial page.
Latest updates to the Mirvetuximab in Platinum-Sensitive Gynecologic Cancer Clinical Trial page
- Check5 days agoChange DetectedThe website has updated the 'type of intervention' feature from version v2.13.3 to v2.14.0, indicating a significant revision.SummaryDifference1%
- Check12 days agoChange DetectedDifference1%
- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedNew updates have been added, including a completion date of 2024-12-20 and an actual date of 2024-12-12, while previous entries such as 'Active, not recruiting' and several estimated dates have been removed.SummaryDifference0.7%
- Check34 days agoChange DetectedThe website has been updated from version 2.13.2 to 2.13.3.SummaryDifference0.3%
- Check41 days agoChange DetectedThe website has updated the contact details section for the study, replacing the previous information with new details and revising the certification dates.SummaryDifference3%
- Check48 days agoChange DetectedAbbVie has added new information regarding the IMGN853-0419 study, including a study director and helpful links, while ImmunoGen, Inc. has been removed from the list.SummaryDifference1%
Stay in the know with updates to Mirvetuximab in Platinum-Sensitive Gynecologic Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Mirvetuximab in Platinum-Sensitive Gynecologic Cancer Clinical Trial page.